TABLE 4.
Current clinical trials in GI cancer targeting MDSCs
| Compound | Type of compound | Intervention | Therapeutic target | Tumor type (Only showed GI Cancer types) | Clinical phase | Trial status | Clinical trial No. |
|---|---|---|---|---|---|---|---|
| Vicriviroc | Small molecule | Pembrolizumab | CCR5 | CRC | Phase 2 | Active, not recruiting | NCT03631407 |
| SX‐682 | Small molecule | Nivolumab | CXCR1/2 | Metastatic CRC | Phase 1 | Recruiting | NCT04599140 |
| INCB001158 | Small molecule | Pembrolizumab | Arginase | CRC and GC | Phase 1 | Active, not recruiting | NCT02903914 |
| L‐BLP25 | Vaccine | CPA+Chemoradiotherapy | MUC1 | RC | Phase 2 | Completed | NCT01507103 |
| ARG1 peptides | Vaccine | N/A | Arginase | CRC | Phase 1 | Recruiting | NCT03689192 |
| VXM01 | Vaccine | N/A | VEGFR2 | Metastatic CRC | Phase 1 | Completed | NCT02718430 |
| DS‐8273a | Antibody | Nivolumab | TRAIL‐R2 | CRC | Phase 1 | Terminated | NCT02991196 |
| Anakinra | Biotech | LV5FU2 + Bevacizumab | VEGF‐A | Metastatic CRC | Phase 2 | Completed | NCT02090101 |
| AZD9150 | Antisense Oligonucleotide | N/A | STAT3 | GI cancer | Phase 2 | Terminated | NCT02417753 |
Abbreviations: GI cancer, gastrointestinal cancer; CRC, colorectal cancer; GC, gastric cancer; RC, rectal cancer; CCR5, C‐C chemokine receptor 5; CXCR1/2, C–X–C motif chemokine receptor 1/2; MUC1, mucin 1; VEGFR2, vascular endothelial growth factor receptor 2; TRAIL‐R2, TNF‐related apoptosis‐inducing ligand receptor 2; VEGF‐A, vascular endothelial growth factor A; STAT3, signal transducer and activator of transcription 3.